Background: In breast cancer patients, a correlation between endothelin-1 (ET-1) and lymph node metastasis was found. While breast cancer with a positive ER status can be treated with Tamoxifen, several studies describe increasing Tamoxifen resistance in patients. We analyzed the relationship between Tamoxifen, ET-1 overexpression, and ER leading to Tamoxifen resistance. Methods: Breast cancer cell lines were treated with Tamoxifen, ET-1, estrogen and combinations. Using qRT-PCR, immune-precipitation, Western blot, EMSA and immunohistology target gene expression and ER complex partners were investigated. Human biopsies and mastectomy specimens were immunohistologically studied for Vimentin 3, and ERβ. Results: Breast cancer cells stimulated with a combination of Tamoxifen and ET-1 downregulate ER α , while upregulating intracellular ET-1, and ERβ. Immunoprecipation of nuclear extracts with ET-1, ER α or ERβ agarose conjugated antibodies reveals a complex formation change replacing ER α by ERβ once Tamoxifen forms a complex with ET-1. ERβand ET-1 migrate into the nucleus. ET-1 stimulation upregulates metastases promoting target genes (IL-6, Wnt11), including a n ovel one, Vimentin 3. Tissue analyses show Vim3 and ERβ expression in metastases of ER α positive breast cancer, and in ER α negative biopsies/m astectomy specimens. Conclusion: We are the first to describe a complex consisting of Tamoxifen, ERβ and ET-1, whose nuclear transmigration causes an overexpression of target genes. This mechanism may explain Tamoxifen resistance. Future pathologic analyses should include estrogen beta receptor status as well as the ET-1 expression. This concept presents a new treatment approach for individualized medicine in breast cancer patients with increased ET-1 levels.
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. (2011) Global Cancer Statistics Tics. CA: A Cancer Journal for Clinicians, 61, 69-90. https://doi.org/10.3322/caac.20107
Gruvberger-Saal, S.K., Bendahl, P.O., Saal, L.H., Laakso, M., Hegardt, C., Eden, P., Peterson, M.P., Isola, J., Borg, A., et al. (2007) Estrogen Receptor Beta Expression Is Associated with Tamoxifen Response in Eralpha-Negative Breast Carcinoma. Clinical Cancer Research, 13, 1987-1994. https://doi.org/10.1158/1078-0432.CCR-06-1823
Jensen, E.V., Desombre, E.R., Kawashima, T., Suzuki, T., Kyser, K. and Jungblut, P.W. (1967) Estrogen-Binding Substances of Target Tissues. Science, 158, 529-530. https://doi.org/10.1126/science.158.3800.529-c
Mosselman, S., Polman, J. and Dijkema, R. (1996) ER Beta: Identification and Characterization of a Novel Human Estrogen Receptor. FEBS Letters, 392, 49-53. https://doi.org/10.1016/0014-5793(96)00782-X
Litwiniuk, M.M., Roznowski, K., Filas, V., Godlewski, D.D., Stawicka, M., Kaleta, R. and Breborowicz, J. (2008) Expression of Estrogen Receptor Beta in the Breast Carcinoma of BRCA1 Mutation Carriers. BMC Cancer, 8, 100. https://doi.org/10.1186/1471-2407-8-100
Hopp, T.A., Weiss, H.L., Parra, I.S., Cui, Y., Osborne, C.K. and Fuqua, S.A. (2004) Low Levels of Estrogen Receptor Beta Protein Predict Resistance to Tamoxifen Therapy in Breast Cancer. Clinical Cancer Research, 10, 7490-7499. https://doi.org/10.1158/1078-0432.CCR-04-1114
Yan, Y., Li, X., Blanchard, A., Bramwell, V.H., Pritchard, K.I., Tu, D., Shepherd, L., Myal, Y., Penner, C., Watson, P.H., et al. (2013) Expression of Both Estrogen Receptor-Beta 1 (ER-beta1) and Its Co-Regulator Steroid Receptor RNA Activator Protein (SRAP) Are Predictive for Benefit from Tamoxifen Therapy in Patients with Estrogen Receptor-Alpha (ER-alpha)-Negative Early Breast Cancer (EBC). Annals of Oncology, 24, 1986-1993. https://doi.org/10.1093/annonc/mdt132
Younes, M. and Honma, N. (2011) Estrogen Receptor Beta. Archives of Pathology & Laboratory Medicine, 135, 63-66.
Murphy, L.C., Leygue, E., Niu, Y., Snell, L., Ho, S.M. and Watson, P.H. (2002) Relationship of Coregulator and Oestrogen Receptor Isoform Expression to De Novo Tamoxifen Resistance in Human Breast Cancer. British Journal of Cancer, 87, 1411-1416. https://doi.org/10.1038/sj.bjc.6600654
Novelli, F., Milella, M., Melucci, E., Di Benedetto, A., Sperduti, I., Perrone-Donnorso, R., Perracchio, L., Venturo, I., Nistico, C., Fabi, A., et al. (2008) A Divergent Role for Estrogen Receptor-Beta in Node-Positive and Node-Negative Breast Cancer Classified According to Molecular Subtypes: An Observational Prospective Study. Breast Cancer Research, 10, R74. https://doi.org/10.1186/bcr2139
Kojima, K. and Nihei, Z. (1995) Expression of Endothelin-1 Immunoreactivity in Breast Cancer. Surgical Oncology, 4, 309-315. https://doi.org/10.1016/S0960-7404(10)80043-X
Matteucci, E., Maroni, P., Luzzati, A., Perrucchini, G., Bendinelli, P. and Desiderio, M.A. (2013) Bone Metastatic Process of Breast Cancer Involves Methylation State Affecting E-Cadherin Expression through TAZ and WWOX Nuclear Effectors. European Journal of Cancer, 49, 231-244. https://doi.org/10.1016/j.ejca.2012.05.006
Tamkus, D., Sikorskii, A., Gallo, K.A., Wiese, D.A., Leece, C., Madhukar, B.V., Chivu, S.C., Chitneni, S. and Dimitrov, N.V. (2013) Endothelin-1 Enriched Tumor Phenotype Predicts Breast Cancer Recurrence. ISRN Oncology, 2013, Article ID: 385398. https://doi.org/10.1155/2013/385398
Yanagisawa, M., Kurihara, H., Kimura, S., Goto, K. and Masaki, T. (1988) A Novel Peptide Vasoconstrictor, Endothelin, Is Produced by Vascular Endothelium and Modulates Smooth Muscle Ca2+ Channels. Journal of Hypertension, 6, S188-S191. https://doi.org/10.1097/00004872-198812040-00056
Irani, S., Salajegheh, A., Smith, R.A. and Lam, A.K. (2014) A Review of the Profile of Endothelin Axis in Cancer and Its Management. Critical Reviews in Oncology/Hematology, 89, 314-321. https://doi.org/10.1016/j.critrevonc.2013.08.011
McKenzie, G.A., Hinsley, E.E., Hunter, K. and Lambert, D.W. (2104) The Endothelin Axis in Head and Neck Cancer: A Promising Therapeutic Opportunity? Journal of Oral Pathology & Medicine, 43, 395-404.
Rosano, L., Spinella, F. and Bagnato, A. (2013) Endothelin 1 in Cancer: Biological Implications and Therapeutic Opportunities. Nature Reviews Cancer, 13, 637-651. https://doi.org/10.1038/nrc3546
Liakou, P., Tepetes, K., Germenis, A., Leventaki, V., Atsaves, V., Patsouris, E., Roidis, N., Hatzitheophilou, K. and Rassidakis, G.Z. (2012) Expression Patterns of Endothelin-1 and Its Receptors in Colorectal Cancer. Journal of Surgical Oncology, 105, 643-649. https://doi.org/10.1002/jso.23017
Montironi, R., Mazzucchelli, R., Barbisan, F., Stramazzotti, D., Santinelli, A., Lopez Beltran, A., Cheng, L., Montorsi, F. and Scarpelli, M. (2007) Immunohistochemical Expression of Endothelin-1 and Endothelin-A and Endothelin-B Receptors in High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer. European Urology, 52, 1682-1689. https://doi.org/10.1016/j.eururo.2007.02.024
Wang, Q.B., Qu, W.S., Qin, D.S. and Wang, Z.P. (2006) Roles of Endothelin and Its Receptors in Prostate Cancer. National Journal of Andrology, 12, 450-452.
Wulfing, C., Eltze, E., Piechota, H., Abol-Enein, H., Wulfing, P., Bode, M.E., Hertle, L. and Sievert, K.D. (2005) Expression of Endothelin-1 and Endothelin-A and -B Receptors in Invasive Bladder Cancer. Oncology Reports, 13, 223-228.
Alanen, K., Deng, D.X. and Chakrabarti, S. (2000) Augmented Expression of Endothelin-1, Endothelin-3 and the Endothelin-B Receptor in Breast Carcinoma. Histopathology, 36, 161-167. https://doi.org/10.1046/j.1365-2559.2000.00795.x
Wulfing, P., Diallo, R., Kersting, C., Wulfing, C., Poremba, C., Rody, A., Greb, R.R., Bocker, W. and Kiesel, L. (2003) Expression of Endothelin-1, Endothelin-A, and Endothelin-B Receptor in Human Breast Cancer and Correlation with Long-Term Follow-Up. Clinical Cancer Research, 9, 4125-4131.
Grimshaw, M.J. (2005) Endothelins in Breast Tumour Cell Invasion. Cancer Letters, 222, 129-138. https://doi.org/10.1016/j.canlet.2004.08.029
Namazi, S., Rouhani Fard, S.A. and Abedtash, H. (2008) Role of Endothelin-1 in Tamoxifen Resistance: Mechanism for a New Possible Treatment Strategy in Breast Cancer. Medical Hypotheses, 70, 109-111. https://doi.org/10.1016/j.mehy.2007.01.092
von Brandenstein, M.G., Ngum Abety, A., Depping, R., Roth, T., Koehler, M., Dienes, H.P. and Fries, J.W. (2008) A p38-p65 Transcription Complex Induced by Endothelin-1 Mediates Signal Transduction in Cancer Cells. Biochimica et Biophysica Acta, 1783, 1613-1622. https://doi.org/10.1016/j.bbamcr.2008.04.003
von Brandenstein, M., Depping, R., Schafer, E., Dienes, H.P. and Fries, J.W. (2011) Protein Kinase C Alpha Regulates Nuclear Pri-microRNA 15a Release as Part of Endothelin Signaling. Biochimica et Biophysica Acta, 1813, 1793-1802. https://doi.org/10.1016/j.bbamcr.2011.06.006
von Brandenstein, M., Puetz, K., Schlosser, M., Loser, M., Kallinowski, J.P., Godde, D., Buettner, R., Storkel, S. and Fries, J.W.U. (2015) Vimentin 3—The New Hope—Differentiating RCC vs. Oncocytoma. Disease Markers, 2015, Article ID: 368534.
Sweeney, E.E., McDaniel, R.E., Maximov, P.Y., Fan, P. and Jordan, V.C. (2012) Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer. Significant Clinical Progress despite Limitations. Hormone Molecular Biology and Clinical Investigation, 9, 143-163.
Mehta, P.P., Whalen, P., Baxi, S.M., Kung, P.P., Yamazaki, S. and Yin, M.J. (2011) Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, Anovel Oral Inhibitor of Hsp 90. Clinical Cancer Research, 17, 5432-5442. https://doi.org/10.1158/1078-0432.CCR-11-0592
Lee, Y.H., Kang, B.S. and Bae, Y.S. (2014) Premature Senescence in Human Breast Cancer and Colon Cancer Cells by Tamoxifen-Mediated Reactive Oxygen Species Generation. Life Sciences, 97, 116-122. https://doi.org/10.1016/j.lfs.2013.12.009
Lukásová, E., Kovarík, A. and Kozubek, S. (2018) Consequences of Lamin B1 and Lamin B Receptor Downregulation in Senescence. Cell, 7, E11.
Bagnato, D., Salani, D., Castro, V., Wu-Wong, J., Nicotra, M., Venuti, A. and Natali, P.G. (1999) Expression of Endothelin 1 and Endothelin A Receptor in Ovarian Carcinoma. Evidence for an Autocrine Role in Tumor Growth. Cancer Research, 59, 720-727.
Schafer, Z.T. and Brugge, J.S. (2007) IL-6 Involvement in Epithelial Cancers. Journal of Clinical Investigation, 117, 3660-3663. https://doi.org/10.1172/JCI34237
Ibrahim, S.A., El-Ghonaimy, E.A., Hassan, H., Mahana, N., Mahmoud, M.A., El-Mamlouk, T., El-Shinawi, M. and Mohamed, M.M. (2016) Hormonal-Receptor Positive Breast Cancer: IL-6 Augments Invasion and Lymph Node Metastasis via Stimulating Cathepsin B Expression. Journal of Advanced Research, 7, 661-670. https://doi.org/10.1016/j.jare.2016.06.007
Jessen, J.R. (2009) Noncanonical Wnt Signaling in Tumor Progression and Metastasis. Zebrafish, 6, 21-28. https://doi.org/10.1089/zeb.2008.0571
Uysal-Onganer, P., Kawano, Y., Caro, M., Walker, M.M., Diez, S., Darrington, R.S., Waxman, J. and Kypta, R.M. (2010) Wnt-11 Promotes Neuroendocrine-Like Differentiation, Survival and Migration of Prostate Cancer Cells. Molecular Cancer Therapeutics, 9, 55. https://doi.org/10.1186/1476-4598-9-55
Dwyer, M., Joseph, J., Wade, H., Eaton, M., Kunder, R.S., Kazmin, D., Chang, C. and McDonnell, D.P. (2010) WNT11 Expression Is Induced by Estrogen-Related Receptor Alpha and Beta-Catenin and Acts in an Autocrine Manner Toincrease Cancer Cell Migration. Cancer Research, 70, 9298-9308. https://doi.org/10.1158/0008-5472.CAN-10-0226
Luga, V., Zhang, L., Viloria-Petit, A.M., Ogunjimi, A.A., Inanlou, M.R., Chiu, E., Buchanan, M., Hosein, A.N., Basik, M. and Wrana, J.L. (2012) Exosomes Mediate Stromal Mobilization of Autocrine Wnt-PCP Signaling in Breast Cancer Cell Migration. Cell, 151, 1542-1556. https://doi.org/10.1016/j.cell.2012.11.024
Ring, A. and Dowsett, M. (2004) Mechanisms of Tamoxifen Resistance. Endocrine-Related Cancer, 11, 643-658. https://doi.org/10.1677/erc.1.00776
Thakkar, D., Shervington, L. and Shervington, A. (2011) Proteomic Studies Coupled with RNAi Methodologies Can Shed Further Light on the Downstream Effects of Telomerase in Glioma. Cancer Investigation, 29, 113-122. https://doi.org/10.3109/07357907.2010.543212
Otsuki, S., Inokuchi, M., Enjoji, M., Ishikawa, T., Takagi, Y., Kato, K., Yamada, H., Kojima, K. and Sugihara, K. (2011) Vimentin Expression Is Associated with Decreased Survival in Gastric Cancer. Oncology Reports, 25, 1235-1242.
Speirs, V., Parkes, A.T., Kerin, M.J., Walton, D.S., Carleton, P.J., Fox, J.N. and Atkin, S.L. (1999) Coexpression of Estrogen Receptor Alpha and Beta. Poor Prognostic Factors in Human Breast Cancer? Cancer Research, 59, 525-528.
Matthews, J. and Gustafsson, J.A. (2003) Estrogen Signaling. A Subtle Balance between ER Alpha and ER Beta. Molecular Interventions, 3, 281-292. https://doi.org/10.1124/mi.3.5.281
Hall, J.M. and McDonnell, D.P. (1999) The Estrogen Receptor Beta-Isoform (ERbeta) of the Human Estrogen Receptor Modulates ERalpha Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens. Endocrinology, 140, 5566-5578. https://doi.org/10.1210/endo.140.12.7179
Grimshaw, M., Hagemann, T., Ayhan, A., Gillett, C., Binder, C. and Balkwill, F. (2004) A Role for Endothelin-2 and Its Receptors in Breast Tumor Cell Invasion. Cancer Research, 64, 2461-2468. https://doi.org/10.1158/0008-5472.CAN-03-1069
Couse, J.F. and Korach, K.S. (1999) Estrogen Receptor Null Mice. What Have We Learned and Where Will They Lead Us? Endocrine Reviews, 20, 358-417. https://doi.org/10.1210/edrv.20.3.0370
Rosano, L., Spinella, F. and Bagnato, A. (2010) The Importance of Endothelin Axis in Initiation, Progression, and Therapy of Ovarian Cancer. AJP Regulatory Integrative and Comparative Physiology, 299, R395-404. https://doi.org/10.1152/ajpregu.00304.2010
Williams-Brown, M.Y., Salih, S.M., Xu, X., Veenstra, T.D., Saeed, M., Theiler, S.K., Diaz-Arrastia, C.R. and Salama, S.A. (2011) The Effect of Tamoxifen and Raloxifene on Estrogen Metabolism and Endometrial Cancer Risk. The Journal of Steroid Biochemistry and Molecular Biology, 126, 78-86. https://doi.org/10.1016/j.jsbmb.2011.05.001
Garcia-Becerra, R., Santos, N., Diaz, L. and Camacho, J. (2013) Mechanisms of Resistance to Endocrine Therapy in Breast Cancer. Focus on Signaling Pathways, miRNAs and Genetically Based Resistance. International Journal of Molecular Sciences, 14, 108-145. https://doi.org/10.3390/ijms14010108
Dahlman-Wright, K., Cavailles, V., Fuqua, S., Jordan, V., Katzenellenbogen, J., Korach, K., Maggi, A., Muramatsu, M., Parker, M. and Gustafsson, J. (2006) International Union of Pharmacology. LXIV Estrogen Receptors. Pharmacological Reviews, 58, 773-781. https://doi.org/10.1124/pr.58.4.8